The PROMISE study: PROphylaxis of MIgraine with SEglor® (dihydroergotamine mesilate) in French primary care

CNS Drugs

Volumn 18, Issue 15, 2004, Pages 1149-1163

  Pradalier, André ^a   Lantéri Minet, Michel ^b   Géraud, Gilles ^c   Allain, Hervé ^d   Lucas, Christian ^e   Delgado, Antonio ^f  

^a HÔPITAL LOUIS MOURIER   (France)

^b PASTEUR HOSPITAL   (France)

^c CHU RANGUEIL   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Schwarz Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE MESILATE; NARCOTIC ANALGESIC AGENT; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FLUSHING; FRANCE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PARESTHESIA; PATIENT COMPLIANCE; PHARYNGITIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PAIN; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; DIHYDROERGOTAMINE; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PRIMARY HEALTH CARE; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 10844219747     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418150-00009     Document Type: Article

References (37)

1. Dahlöf CG, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31-6
2. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34: 337-43
3. Richard A, Henry P, Chazot G, et al. Quality of life and migraine: validation of the QVM questionnaire in hospital consultation and in general medicine [in French]. Therapie 1993; 48: 89-96
4. Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000; 55: 624-9
5. Mathew NT, Kurman R, Perez F. Drug induced refractory headache: clinical features and management. Headache 1990; 30: 634-8
6. Rapoport AM. Pharmacological prevention of migraine. Clin Neurosci 1998; 5: 55-9
7. Lantéri-Minet M. Analgesic-induced chronic headaches. Pathol Biol 2000; 48: 707-14
8. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1997; 17: 67-72
9. Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). Diagnostic and therapeutic management of migraine in adults and children. Clinical and economic aspects; recommendations [online]. Available from URL: http://www.anaes.fr [Accessed 2002 Oct]
10. Lantéri-Minet M, Alchaar H, Besson G, et al. Prophylaxis for migraine headache: a pharmacoepidemiological study of practices used by primary care physicians and neurologists in France. Rev Neurol (Paris) 2000; 156: 1106-12
11. Langohr HD, Reinecke M, Gerber WD, et al. Dihydroergotamine and flunarizine in the prevention of migraine: a comparative double-blind study. Fortschr Med 1988; 106: 65-70
12. Martucci N, Manna V, Mattesi P, et al. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation. Cephalalgia 1983; 3 Suppl. 1: 151-5
13. Neuman M, Demarez JP, Harmey JL, et al. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharmacol Res 1986; 6: 11-3
14. Pradalier A, Dry J, Loisy B, et al. Comparative study of indoramin versus dihydroergotamine in the preventive treatment of migraine. Therapie 1988; 43: 293-7
15. Aylward M, Davies DE, Maddock J, et al. On the treatment of migraine: pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human. Cephalalgia 1983; 3 Suppl. 1: 146-50
16. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765-86
17. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
18. Ventafridda V, Saita L, Ripamonti C, et al. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 1985; 7: 93-6
19. Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life questionnaire. Headache 1998; 38: 295-302
20. Steiner TJ, Ahmed F, Findley LJ, et al. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18: 283-6
21. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997; 37 Suppl. 1: 15-25
22. Lance JW. Current concepts of migraine pathogenesis. Neurology 1993; 43 Suppl. 3: 11-5
23. 1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 682-8
24. 1A receptor agonists in the rat brain. Br J Pharmacol 2003; 139: 424-34
25. 1A and 5-HT2B/2C serotonin receptors: potential targets for the preventive treatment of migraine. Rev Neurol (Paris) 2002; 158 Suppl. 2: 190
26. 2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol 2003; 140: 277-84
27. Merikangas KR. Association between psychopathology and headache syndromes. Curr Opin Neurol 1995; 8: 248-51
28. Radat F. Psychopathology and headache. Rev Neurol (Paris) 2000; 156 Suppl. 4: 62-7
29. Stewart W, Breslau N, Keck PE. Comorbidity of migraine and panic disorder. Neurology 1994; 44 Suppl. 7: 23-7
30. Diener HC, Föh M, Iaccarino C, et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 1996; 16: 441-7
31. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997; 54: 1141-5
32. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103-8
33. van de Ven LLM, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 1997; 17: 596-9
34. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998; 50: 466-70
35. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22: 523-32
36. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 1989; 29: 633-8
37. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache 1989; 29: 639-42